| GTO ID | GTC2845 |
| Trial ID | NCT05122221 |
| Disease | Anal Canal Cancer | Cervical Cancer | Head and Neck Cancer |
| Altered gene | CRTE7A2-01 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | CRTE7A2-01 TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cell for HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
| Year | 2021 |
| Country | China |
| Company sponsor | Corregene Biotechnology Co., Ltd |
| Other ID(s) | CRTE7A2-2107C |
| Cohort 1 | |||||||||
|
|||||||||